Sintilimab plus GemOx is an effective salvage therapy in patients with refractory/relapsing nodal peripheral T cell lymphomas.

Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902060 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-1335 (Electronic) Linking ISSN: 01715216 NLM ISO Abbreviation: J Cancer Res Clin Oncol Subsets: MEDLINE

Original Publication: Berlin ; New York : Springer-Verlag.

Salvage Therapy*/methods ; Lymphoma, T-Cell, Peripheral*/drug therapy ; Lymphoma, T-Cell, Peripheral*/pathology ; Antibodies, Monoclonal, Humanized*/administration & dosage ; Antibodies, Monoclonal, Humanized*/therapeutic use ; Antibodies, Monoclonal, Humanized*/adverse effects ; Antineoplastic Combined Chemotherapy Protocols*/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols*/adverse effects ; Gemcitabine* ; Deoxycytidine*/analogs & derivatives ; Deoxycytidine*/administration & dosage ; Deoxycytidine*/therapeutic use ; Deoxycytidine*/adverse effects; Humans ; Male ; Female ; Middle Aged ; Retrospective Studies ; Adult ; Aged ; Oxaliplatin/administration & dosage ; Oxaliplatin/adverse effects ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/pathology ; Young Adult ; Organoplatinum Compounds

Purpose: The retrospective study was to explore the effectiveness and safety of GemOx (gemcitabine, oxaliplatin) plus sintilimab (belongs to the class of drugs known as immune checkpoint inhibitors, particularly targeting the PD-1 receptor) in relapse or refractory nodal PTCLs.
Methods: Patients with nodal PTCL who initiated salvage therapy with sintilimab and GemOx between January 2020 to September 2021 were identified from the database of the hematology department of the Second Affiliated Hospital of Zhejiang University School of Medicine. All patients received 2-4 cycles (3 weeks/cycle) of treatment of sintilimab (200 mg, I.V, D1) in combination with GemOx. Treatment response was assessed every six weeks during the salvage treatment phase. Eligible patients received maintenance therapy according to the investigator's decision. Follow-ups were routinely conducted every three months.
Results: 31 patients with r/r nodal PTCLs were enrolled, including 23 PTCL-NOS, 4 AITL, and 4 ALCL. 21 (67.7%) patients received at least two lines of therapy. 71.0% (95% CI, 53.4%-83.9%) of patients documented objective response of 2-4 cycles of sintilimab plus GemOx therapy, including 9 complete response and 13 partial response. 21 (67.7%) patients received consolidation therapy, including 5 autologous stem-cell transplantation and 12 histone deacetylase inhibitors. After a median 25.6 months follow-up, the median PFS was 22.0 (95% CI,11.8-24.7) months, and the median OS was 26.2 (95% CI, 24.4 -NA) months. 29 (93.5%) patients experienced at least one adverse event, and 26 (83.9% patients only had mild (grade 1-2) AEs.Univariable Cox regression showed the progression risk of AITL is 22.7 (3.9- 131.0, p < 0.01) times of PTCL-NOS, while the HR of ALCL was 1.14 (0.33-3.96,p = 0.833).
Conclusion: Sintilimab plus GemOx showed encouraging activity and manageable toxicity for patients with r/r PTCL.
(© 2024. The Author(s).)

BMJ. 2022 Apr 19;377:e068714. (PMID: 35440464)
Blood. 2014 Sep 4;124(10):1570-7. (PMID: 25006130)
Nat Rev Cancer. 2020 Jun;20(6):323-342. (PMID: 32249838)
Hematology. 2019 Dec;24(1):392-398. (PMID: 30890046)
Blood. 2016 May 19;127(20):2375-90. (PMID: 26980727)
Cancers (Basel). 2022 May 08;14(9):. (PMID: 35565460)
J Clin Oncol. 2013 Sep 1;31(25):3100-9. (PMID: 23897963)
Signal Transduct Target Ther. 2021 Oct 27;6(1):365. (PMID: 34702811)
Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):356-364.e3. (PMID: 31029646)
J Hematol Oncol. 2021 Jan 12;14(1):12. (PMID: 33436023)
Haematologica. 2022 Nov 01;107(11):2675-2684. (PMID: 35320921)
J Clin Oncol. 2008 Sep 1;26(25):4124-30. (PMID: 18626005)
J Clin Oncol. 2014 Sep 20;32(27):3059-68. (PMID: 25113753)
Am J Clin Pathol. 2012 Sep;138(3):429-34. (PMID: 22912361)
Blood. 2016 Sep 8;128(10):1374-81. (PMID: 27418641)
J Thorac Oncol. 2021 Dec;16(12):2109-2120. (PMID: 34358724)
Ann Oncol. 2015 Aug;26(8):1766-71. (PMID: 26105599)

Keywords: Chemoimmunotherapy; GemOx; PTCL; Salvage therapy; Sintilimab

8FU7FQ8UPK (sintilimab)
0 (Antibodies, Monoclonal, Humanized)
0 (Gemcitabine)
0W860991D6 (Deoxycytidine)
04ZR38536J (Oxaliplatin)
0 (Organoplatinum Compounds)

gemcitabine-oxaliplatin regimen

Date Created: 20240919 Date Completed: 20240919 Latest Revision: 20240921

20240921

10.1007/s00432-024-05956-3

39299973